Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.60 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.56 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | FGF1 | P05230 | 1/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14227913 | 1.00 | CD209 (0.60) | CD209ENGASELGALS8GAALGALS3 | |
| SCHEMBL11220673 | 1.00 | CD209 (0.60) | CD209ENGASELGALS8GAALGALS3 | |
| SCHEMBL14199396 | 1.00 | CD209 (0.60) | CD209ENGASELGALS8GAALGALS3 | |
| SCHEMBL13659933 | 1.00 | CD209 (0.60) | CD209ENGASELGALS8GAALGALS3 | |
| SCHEMBL6815714 | 1.00 | CD209 (0.60) | CD209ENGASELGALS8GAALGALS3 | |
| SCHEMBL11220668 | 1.00 | CD209 (0.60) | CD209ENGASELGALS8GAALGALS3 | |
| SCHEMBL14227992 | 1.00 | CD209 (0.60) | CD209ENGASELGALS8GAALGALS3 | |
| SCHEMBL17830236 | 1.00 | CD209 (0.60) | CD209ENGASELGALS8GAALGALS3 | |
| SCHEMBL13290316 | 1.00 | CD209 (0.60) | CD209ENGASELGALS8GAALGALS3 | |
| SCHEMBL13227578 | 0.97 | CD209 (0.57) | CD209ENGASELGALS8GAALGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694924-A2 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES | Rock Biomedical Inc. (TW) | 2026-02-18 | — | — | EP | claimed |
| US-20260014089-A1 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY | ROCK BIOMEDICAL INC (TW) | 2026-01-15 | — | — | US | claimed |
| US-12508235-B2 | Methods and compositions for dendritic cell targeting nano-delivery | ROCK BIOMEDICAL, INC. (TW) | 2025-12-30 | — | — | US | claimed |
| EP-4661844-A2 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY | Rock Biomedical Inc. (TW) | 2025-12-17 | — | — | EP | claimed |
| EP-4568709-A2 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES | Rock Biomedical Inc. (TW) | 2025-06-18 | — | — | EP | claimed |
| US-12318485-B2 | Methods and compositions for targeted delivery by polymersomes | ROCK BIOMEDICAL, INC. (TW) | 2025-06-03 | — | — | US | claimed |
| US-20250041222-A1 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES | ROCK BIOMEDICAL INC. (TW) | 2025-02-06 | — | — | US | claimed |
| US-20240366516-A1 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY | ROCK BIOMEDICAL INC. (TW) | 2024-11-07 | — | — | US | claimed |
| US-20240366517-A1 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES | ROCK BIOMEDICAL INC (TW) | 2024-11-07 | — | — | US | claimed |
| WO-2024215616-A2 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES | ROCK BIOMEDICAL INC. (TW) | 2024-10-17 | — | — | WO | claimed |
| WO-2024215614-A2 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY | ROCK BIOMEDICAL INC. (TW) | 2024-10-17 | — | — | WO | claimed |
| WO-2024215612-A2 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES | ROC BIOMEDICAL INC. (TW) | 2024-10-17 | — | — | WO | claimed |
| US-12576134-B2 | Antiviral lectin and uses thereof | ACADEMIA SINICA (TW) | 2026-03-17 | — | — | US | disclosed |
| EP-4694924-A2 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES | Rock Biomedical Inc. (TW) | 2026-02-18 | — | — | EP | disclosed |
| US-20260014089-A1 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY | ROCK BIOMEDICAL INC (TW) | 2026-01-15 | — | — | US | disclosed |
| US-20260000609-A1 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES | ROCK BIOMEDICAL INC (TW) | 2026-01-01 | — | — | US | disclosed |
| US-5725804-A | ALBUMIN PARTICLES STABLE TO RESOLUBILIZATION, POLYOXYETHYLENE GLYCOL, ALCOHOL | HEMOSPHERE, INC. (US) | 1998-03-10 | — | — | US | disclosed |
| US-5616311-A | AQUEOUS ALBUMIN SUSPENSION STABILIZED BY HEMOGLOBIN PARTICLES | HEMOSPHERE, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0475160-B1 | Preparation for drug application in minute droplet form | IDEA AG (DE) | 1996-02-14 | — | — | EP | disclosed |
| EP-0475160-A1 | Preparation for drug application in minute droplet form | Cevc, Gregor, Prof. Dr. (DE) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366517-A1 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING VACCINES | CD4, CD2BP2, CD14 | CD209 13/4885ENGASE 720/4885LGALS8 615/4885 |
| US-12318485-B2 | Methods and compositions for targeted delivery by polymersomes | ALG1, CHMP4B, ALG8 | CD209 2971/4885ENGASE 73/4885LGALS8 242/4885 |
| US-20260000609-A1 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES | CD2, CLEC4M, CD47 | CD209 16/4885ENGASE 305/4885LGALS8 54/4885 |
| US-20250041222-A1 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY BY POLYMERSOMES | ALG1, CHMP4B, ALG8 | CD209 2971/4885ENGASE 73/4885LGALS8 242/4885 |
| US-20240366516-A1 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY | LCP2, CD4, LNPEP | CD209 16/4885ENGASE 372/4885LGALS8 358/4885 |
| US-20260014089-A1 | METHODS AND COMPOSITIONS FOR DENDRITIC CELL TARGETING NANO-DELIVERY | CD4, LY6K, CLEC4M | CD209 4/4885ENGASE 631/4885LGALS8 159/4885 |
| US-12508235-B2 | Methods and compositions for dendritic cell targeting nano-delivery | CD4, CD47, LY6K | CD209 25/4885ENGASE 117/4885LGALS8 97/4885 |
| US-12576134-B2 | Antiviral lectin and uses thereof | NEU3, NEU2, FUCA2 | CD209 589/4885ENGASE 18/4885LGALS8 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.